Adynxx, Inc.

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

Venture capital investment in US biopharmaceutical companies fell $2.1bn from $9.89bn in 2015 to $7.79bn in 2016, but it was still the second highest amount of VC cash invested in US drug development

The table records clinical developments using data from Informa Pharma Intelligence’s Biomedtracker. It lists drugs for which an important event was recorded between Feb. 24 and March 2, 2017, divided

Projected to reach $6 billion in worldwide revenues by year’s end, the business of advanced wound care has transformed from a sleepy commoditized marketplace to a robust high-growth, hi-tech arena whe